Strides Pharma Science Ltd on Tuesday said its wholly-owned arm has received approval from the US health regulator for its generic version of Icosapent Ethyl capsules used to control triglyceride levels in the blood. The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte.

Strides Pharma Science Ltd星期二表示，其合资企业已获得美国卫生监管机构的批准，用于控制血液中甘油三酯水平的通用版二十碳五烯酸乙酯胶囊。美国食品和药物管理局（USFDA）批准Strips Pharma Global Pte。

Limited, Singapore, is for Icosapent Ethyl Capsules 0.5 gram and 1 gram, Strides Pharma Science said in a regulatory filing. The product is bioequivalent and therapeutically equivalent to the reference listed drug Vascepa of Amarin. Enhance Your Healthcare Expertise with High-Impact CoursesOffering CollegeCourseWebsiteIIM KozhikodeIIMK Healthcare Management & Analytics ProgrammeVisitIndian School of BusinessISB Healthcare ManagementVisit It will be manufactured at the company's facility in Bengaluru, it added.

有限公司，新加坡，用于二十碳五烯酸乙酯胶囊0.5克和1克，Strides Pharma Science在监管文件中说。该产品与Amarin的参考列出的药物Vascepa具有生物等效性和治疗等效性。通过高影响力的课程提高您的医疗保健专业知识提供大学课程网站KozhikodeIIMK医疗保健管理与分析计划美国商业学院ISB医疗保健管理访问它将在班加罗尔的公司工厂制造。

The Icosapent Ethyl capsules have a market size of around USD 1.3 billion, Strides said, citing IQVIA..

Strips引用IQVIA说，二十碳五烯酸乙酯胶囊的市场规模约为13亿美元。。